| 1 | 403484 | [Treatment of advanced breast cancer with alkylating agents]. | Minerva Med | 1977 Mar 17 |
4 |
| 2 | 413765 | [Genetic control of mutability in laboratory mice. I. Genetic analysis of the sensitivity of mice of strains 101/H and C57BL/6 to the mutagenic effect of thio-TEPA]. | Genetika | 1977 |
1 |
| 3 | 1634926 | Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. | J Clin Oncol | 1992 Aug |
1 |
| 4 | 2105156 | Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. | Cancer Res | 1990 Feb 1 |
1 |
| 5 | 2491884 | Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies. | J Clin Oncol | 1989 Jan |
1 |
| 6 | 2504483 | Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide. | Cancer Res | 1989 Sep 15 |
2 |
| 7 | 3086117 | [Effect of thiophosphamide on ceruloplasmin activity and the copper content of the blood of rabbits]. | Farmakol Toksikol | 1986 Mar-Apr |
1 |
| 8 | 3107916 | Enhancement and attenuation of cytogenetic damage by vitamin C in cultured human lymphocytes exposed to thiotepa or L-ethionine. | Cytogenet Cell Genet | 1987 |
12 |
| 9 | 4207512 | [Vitamin (B-1 and B2) balance and the antitoxic function of the liver under conditions of experimental thiophosphamide therapy]. | Farmakol Toksikol | 1973 May-Jun |
1 |
| 10 | 4251799 | [The effect of thiophosphamide on the ATP-ase activity of the strucuural and water-soluble proteins of Guerin carcinoma and its drug resistant variant]. | Vopr Med Khim | 1970 Jul-Aug |
1 |
| 11 | 4306223 | [Effect of adrenalectomy, adrenaline and ACTH on the antineoplastic action and antimitotic effect of thiophosphamide]. | Farmakol Toksikol | 1969 Mar-Apr |
1 |
| 12 | 4963995 | An experimental comparative study of the distribution of P32-labelled Thio-Tepa and P32 tag. | Med Radiol (Mosk) | 1967 Apr |
1 |
| 13 | 4972953 | [Levels of properdin in the serum of rats submitted to the combined effect of zymosan and thio-TEPA]. | Klin Lech Zlokach Novoobraz | 1968 |
1 |
| 14 | 5002317 | [Reduction of the toxic effect of thio-tepa on mice using anti-somatotropin serum]. | Biull Eksp Biol Med | 1971 Dec |
1 |
| 15 | 7579367 | An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. | Blood | 1995 Nov 15 |
1 |
| 16 | 7616408 | Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. | J Pharmacol Exp Ther | 1995 Jul |
7 |
| 17 | 7712478 | The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. | Cancer Res | 1995 Apr 15 |
10 |
| 18 | 8206865 | Cell-adhesive activity and receptor-binding specificity of the laminin-derived YIGSR sequence grafted onto Staphylococcal protein A. | J Biochem | 1994 Feb |
1 |
| 19 | 8475071 | Acquired multicellular-mediated resistance to alkylating agents in cancer. | Proc Natl Acad Sci U S A | 1993 Apr 15 |
1 |
| 20 | 8612310 | A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. | Cancer Chemother Pharmacol | 1996 |
2 |
| 21 | 9548807 | Induction of p53 by the concerted actions of aziridine and quinone moieties of diaziquone. | Chem Res Toxicol | 1998 Apr |
1 |
| 22 | 9726020 | Comparison of mutant frequencies and types of mutations induced by thiotepa in the endogenous Hprt gene and transgenic lacI gene of Big Blue rats. | Mutat Res | 1998 Jul 17 |
8 |
| 23 | 9788613 | Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells. | Cancer Res | 1998 Oct 15 |
4 |
| 24 | 10069464 | Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa. | Carcinogenesis | 1999 Feb |
3 |
| 25 | 10334868 | Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. | Arch Biochem Biophys | 1999 Jun 1 |
3 |
| 26 | 10482945 | Inappropriate antidiuretic hormone secretion after high-dose thiotepa. | Bone Marrow Transplant | 1999 Sep |
1 |
| 27 | 10556952 | Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. | Bone Marrow Transplant | 1999 Nov |
1 |
| 28 | 10634173 | CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. | J Hematother Stem Cell Res | 1999 Aug |
1 |
| 29 | 10928097 | Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate. | Anticancer Res | 2000 May-Jun |
2 |
| 30 | 11431349 | Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N',N"-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo. | Cancer Res | 2001 Jul 1 |
2 |
| 31 | 11468938 | A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. | J Pharmacokinet Pharmacodyn | 2001 Jun |
1 |
| 32 | 11950782 | Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. | Drug Metab Dispos | 2002 May |
11 |
| 33 | 12107550 | Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. | Cancer Chemother Pharmacol | 2002 Jun |
9 |
| 34 | 12402145 | A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients. | Br J Cancer | 2002 Nov 4 |
1 |
| 35 | 12676886 | The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. | J Pharmacol Exp Ther | 2003 Jul |
4 |
| 36 | 13944000 | [3 cases of bone marrow aplasia, 1 of which is curable, due to triethylene thio-phosphoramide of RP 10, 090]. | Lyon Med | 1962 Sep 23 |
1 |
| 37 | 14495833 | Isolation perfusion and oxygen saturation: the effect on the binding of P-32 tagged triethylene thiophosphoramide. | Surg Forum | 1961 |
1 |
| 38 | 15121764 | Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. | J Pharmacol Exp Ther | 2004 Sep |
4 |
| 39 | 15155554 | Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. | Drug Metab Dispos | 2004 Jun |
3 |
| 40 | 15319333 | CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. | Drug Metab Dispos | 2004 Sep |
1 |
| 41 | 15652242 | Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based. | Biochem Pharmacol | 2005 Feb 1 |
4 |
| 42 | 15838656 | Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. | Cancer Chemother Pharmacol | 2005 Oct |
2 |
| 43 | 16294610 | Bladder cancer: current optimal intravesical treatment. | Urol Nurs | 2005 Oct |
1 |
| 44 | 16874990 | Triethylene thiophosphoramide (thio-tepa) and pterygium. | Am J Ophthalmol | 1966 May |
1 |
| 45 | 17003847 | RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. | Methods Find Exp Clin Pharmacol | 2006 Sep |
2 |
| 46 | 17682072 | A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. | Drug Metab Dispos | 2007 Nov |
2 |
| 47 | 19031971 | High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer. | Anticancer Res | 2008 Sep-Oct |
1 |
| 48 | 19076156 | Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. | Br J Clin Pharmacol | 2009 Jan |
11 |
| 49 | 19616568 | Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. | Toxicol Appl Pharmacol | 2009 Nov 15 |
2 |
| 50 | 21196304 | DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. | Front Biosci (Elite Ed) | 2011 Jan 1 |
4 |